# Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

> **NCT02100813** · PHASE1,PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 220 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** LEO 43204
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02100813
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100813, "Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02100813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*